The New Front Line of STI Diagnosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The New Front Line of STI Diagnosis

  • By

  • Nikolina Babic

  • Sheldon Campbell

  • Kate Crawford

  • November 18, 2026

  • 7 min

Share

Clinical Scorecard: The New Front Line of STI Diagnosis

At a Glance

CategoryDetail
ConditionSexually transmitted infections, including chlamydia, gonorrhea, syphilis, HIV, Mycoplasma genitalium, and Trichomonas vaginalis
Key MechanismsPOC assays provide results near the patient, typically within minutes to an hour. Rapid antibody and antigen-antibody tests for syphilis and HIV commonly use fingerstick whole blood and return results in under 30 minutes; rapid molecular nucleic acid amplification tests detect chlamydia and gonorrhea in approximately 20 minutes.
Target PopulationPeople undergoing STI testing, including adolescents and young adults, men who have sex with men, pregnant people, racial and ethnic minority populations, people with limited access to health care, people experiencing homelessness, migrants, and people with unstable housing or insurance coverage.
Care SettingClinical, public health, community-based, and other care settings where same-visit results are useful, especially when follow-up may be difficult.

Key Highlights

  • Many STIs are asymptomatic, and delayed diagnosis can contribute to complications and continued transmission.
  • Rapid molecular POC assays for chlamydia and gonorrhea can provide results in approximately 20 minutes, with accuracy approaching laboratory-based testing.
  • Same-visit results can support diagnosis and treatment during one encounter and reduce dependence on follow-up visits.
  • POC testing may reduce reliance on syndromic treatment and unnecessary antibiotic exposure.
  • POC testing has limitations, including cost, operational complexity, specimen restrictions, and the need for training and quality oversight.

Guideline-Based Recommendations

Diagnosis

  • Select POC tests according to the organism, assay performance, and approved specimen types.
  • FDA-cleared, CLIA-waived rapid molecular assays are available for chlamydia and gonorrhea; some newer platforms also test for Mycoplasma genitalium and Trichomonas vaginalis.
  • POC tests for herpes simplex virus and human papillomavirus are not yet available.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        STI testing is relevant across populations; the article identifies adolescents and young adults, men who have sex with men, pregnant people, racial and ethnic minority populations, people with limited access to care, people experiencing homelessness, migrants, and people with unstable housing or insurance coverage as groups at increased risk or facing barriers to care.

        The article provides no drug regimens or dosing. Same-visit diagnosis may allow treatment to begin immediately and reduce reliance on empiric treatment.

        Clinical Best Practices

        • Match the POC assay and specimen to the organism and the test's approved use.
        • Integrate POC testing with staff training, competency assessment, quality control, and laboratory oversight.
        • Consider access barriers and the likelihood of follow-up when selecting a testing approach.
        • Use POC testing as a complement to centralized laboratory services, not as a replacement.

        Related Resources & Content

          Original Source(s)

          Related Content